About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: MNKD
- CUSIP: 56400P20
- Previous Close: $0.53
- 50 Day Moving Average: $0.624
- 200 Day Moving Average: $0.662
- 52-Week Range: $478,376,000.00 - $0.41
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.92
- P/E Growth: 0.170
- Market Cap: $251.63M
- Outstanding Shares: 478,376,000
- Beta: 3.26
- Return on Equity: -15.95%
- Return on Assets: 46.57%
Companies Related to MannKind Corporation:
- Debt-to-Equity Ratio: -0.62%
- Current Ratio: 0.46%
- Quick Ratio: 0.41%
What is MannKind Corporation's stock symbol?
MannKind Corporation trades on the NASDAQ under the ticker symbol "MNKD."
Where is MannKind Corporation's stock going? Where will MannKind Corporation's stock price be in 2017?
5 equities research analysts have issued 12-month target prices for MannKind Corporation's shares. Their predictions range from $0.10 to $0.70. On average, they anticipate MannKind Corporation's stock price to reach $0.32 in the next twelve months.
When will MannKind Corporation announce their earnings?
MannKind Corporation is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns MannKind Corporation stock?
MannKind Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.06%), Harel Insurance Investments & Financial Services Ltd. (0.62%), GSA Capital Partners LLP (0.52%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own MannKind Corporation stock include Hakan Edstrom, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.
Who bought MannKind Corporation stock? Who is buying MannKind Corporation stock?
MannKind Corporation's stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and State Street Corp. Company insiders that have bought MannKind Corporation stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.
How do I buy MannKind Corporation stock?
Shares of MannKind Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MannKind Corporation stock cost?
One share of MannKind Corporation stock can currently be purchased for approximately $0.53.